Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107359 | USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents.... | 05/03/2012 |
| 20120045430 | DENDRIMER-LIKE MODULAR DELIVERY VECTOR Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, ca... | 02/23/2012 |
| 20120039936 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furtherm... | 02/16/2012 |
| 20120009217 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regu... | 01/12/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110300181 | PURIFICATION OF VACCINIA VIRUS- AND RECOMBINANT VACCINIA VIRUS-BASED VACCINES The present invention relates to methods for purification of Vaccinia viruses (W) and/or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus p... | 12/08/2011 |
| 20110293658 | USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galact... | 12/01/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110287089 | USE OF A SACCHAROMYCES CEREVISIAE MITOCHONDRIAL NUCLEIC ACIDS FRACTION FOR IMMUNE STIMULATION The present invention relates to the use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction and an antigen for the preparation of a pharmaceutical composition intended to orient the immune response toward a Th1 type response directed against said ... | 11/24/2011 |
| 20110274649 | T-CELL VACCINATION WITH VIRAL VECTORS VIA MECHANICAL EPIDERMAL DISRUPTION Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount... | 11/10/2011 |
| 20110268762 | IMMUNIZATION OF AVIANS BY MUCOSAL ADMINISTRATION OF NON-REPLICATING VECTORED VACCINES The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant hum... | 11/03/2011 |
| 20110223195 | COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian... | 09/15/2011 |
| 20110212131 | METHOD FOR ENHANCING AN IMMUNE RESPONSE A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be use... | 09/01/2011 |
| 20110212123 | Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least ... | 09/01/2011 |
| 20110182932 | MODIFIED VACCINIA ANKARA VIRUS VARIANT The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes whe... | 07/28/2011 |
| 20110182933 | MODIFIED VACCINIA ANKARA VIRUS VARIANT The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes whe... | 07/28/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110150940 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or... | 06/23/2011 |
| 20110142881 | TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular ... | 06/16/2011 |
| 20110142877 | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents.... | 06/16/2011 |
| 20110135685 | Edible Vaccines Expressed in Soybeans The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer an... | 06/09/2011 |
| 20110135598 | METHODS TO DIAGNOSE AND IMMUNIZE AGAINST THE VIRUS CAUSING HUMAN MERKEL CELL CARCINOMA The present invention provides isolated or substantially purified polypeptides, nucleic acids, and virus-like particles (VLPs) derived from a Merkel cell carcinoma virus (MCV), which is a newly-discovered virus. The invention further provides monoclonal antibody molecul... | 06/09/2011 |
| 20110129489 | METHODS FOR GENERATING AN IMMUNE RESPONSE USING DNA AND A VIRAL VECTOR The present invention relates to the generation of an immune response against a target antigen using a DNA and viral vector in a specific administration pattern.... | 06/02/2011 |
| 20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.... | 05/12/2011 |
| 20110081368 | Protein vaccines against poxviruses The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A2... | 04/07/2011 |
| 20110064757 | NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for i... | 03/17/2011 |
| 20110064768 | Immunogenic Compositions An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.... | 03/17/2011 |
| 20110064769 | VV PROMOTER-DRIVEN OVEREXPRESSION OF RECOMBINANT ANTIGENS The present invention is directed to the use of a pharmaceutical composition comprising a vaccinia virus (VV) based vector construct under the control of a strong VV specific promoter. The present invention is in particular directed to the use of this pharmaceutical com... | 03/17/2011 |
| 20110014234 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMA VIRUSES The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regu... | 01/20/2011 |
| 20110002961 | Interleukin 12 paracrine gene delivery enhanced CTL immunotherapy A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule,... | 01/06/2011 |
| 20100322896 | MOLECULAR ADJUVANT This invention relates to the use of a molecular adjuvant to generate an immune response in a host. In particular, the molecular adjuvant may be a TLR signalling pathway component, a co-stimulatory molecule, an NKG2D ligand, IL- or IL-15.... | 12/23/2010 |
| 20100310602 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L<... | 12/09/2010 |
| 20100303859 | VECTORS AND METHOD FOR GENETIC IMMUNIZATION Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a nov... | 12/02/2010 |
| 20100303894 | POX VIRIDAE TREATMENT A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may... | 12/02/2010 |
| 20100285099 | VACCINATION BY TRANSCUTANEOUS TARGETING The present invention relates to a method of vaccination via hair follicles that makes it possible to target vaccine components to the antigen-presenting cells in order to induce a protective and effective immune response against pathogens.... | 11/11/2010 |
| 20100285066 | CANINE LEISHMANIA VACCINE The present invention provides vectors that contain and express in vivo Leishmania KMP11 or an epitope thereof that elicits an immune response in a dog against Leishmania, compositions comprising said vectors, methods of vaccination against Leishmania | 11/11/2010 |
| 20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclos... | 11/11/2010 |
| 20100285065 | MODIFIED CEA NUCLEIC ACID AND EXPRESSION VECTORS The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigen... | 11/11/2010 |
| 20100254981 | Secreted/Cell Bound Poxvirus Proteins and Methods of Use Thereof as Vaccines and Anti-Viral Agents Compositions and methods for the treatment and prevention of pox virus infections are disclosed.... | 10/07/2010 |
| 20100255032 | Parapoxviruses in combination with other antiviral agents for the treatment of viral diseases The present invention relates to the use of Parapoxviruses in combination with other agents for the treatment of viral diseases, and in particular HIV infections and AIDS. The invention also relates to methods for producing medicaments based on combinations of 10/07/2010 | |
